Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.
Identifieur interne : 003649 ( PubMed/Checkpoint ); précédent : 003648; suivant : 003650Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.
Auteurs : Werner Poewe [Autriche] ; Christoph ScherflerSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Brain (radionuclide imaging), Corpus Striatum (radionuclide imaging), Diagnosis, Differential, Dopamine Plasma Membrane Transport Proteins, Humans, Membrane Glycoproteins, Membrane Transport Proteins (analysis), Nerve Tissue Proteins, Neural Pathways (radionuclide imaging), Neurodegenerative Diseases (radionuclide imaging), Parkinson Disease (radionuclide imaging), Parkinsonian Disorders (radionuclide imaging), Sensitivity and Specificity, Substantia Nigra (radionuclide imaging), Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
- MESH :
- chemical , analysis : Membrane Transport Proteins.
- chemical : Dopamine Plasma Membrane Transport Proteins, Membrane Glycoproteins, Nerve Tissue Proteins.
- radionuclide imaging : Brain, Corpus Striatum, Neural Pathways, Neurodegenerative Diseases, Parkinson Disease, Parkinsonian Disorders, Substantia Nigra.
- Diagnosis, Differential, Humans, Sensitivity and Specificity, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
Abstract
We discuss the potential role of dopamine transporter (DAT) imaging by single photon emission computed tomography (SPECT) as a biological marker for differentiating among parkinsonian disorders in routine clinical practice, and the implication for disease progression assessment is considered. Although clinical criteria enable accurate and reliable diagnosis of fully developed Parkinson's disease, there are several areas of diagnostic uncertainty relating to atypical parkinsonian disorders, isolated tremor symptoms not fulfilling essential tremor criteria, as well as drug-induced and psychogenetic parkinsonism. DAT-SPECT facilitates differential diagnosis of the different parkinsonian syndromes that cannot be reliably separated on clinical grounds and it can thus provide valuable diagnostic information in early disease.
DOI: 10.1002/mds.10573
PubMed: 14531041
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:14531041Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria. werner.poewe@uibk.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Scherfler, Christoph" sort="Scherfler, Christoph" uniqKey="Scherfler C" first="Christoph" last="Scherfler">Christoph Scherfler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14531041</idno><idno type="pmid">14531041</idno><idno type="doi">10.1002/mds.10573</idno><idno type="wicri:Area/PubMed/Corpus">003683</idno><idno type="wicri:Area/PubMed/Curation">003683</idno><idno type="wicri:Area/PubMed/Checkpoint">003649</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria. werner.poewe@uibk.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University Hospital, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Scherfler, Christoph" sort="Scherfler, Christoph" uniqKey="Scherfler C" first="Christoph" last="Scherfler">Christoph Scherfler</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Brain (radionuclide imaging)</term><term>Corpus Striatum (radionuclide imaging)</term><term>Diagnosis, Differential</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Humans</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins (analysis)</term><term>Nerve Tissue Proteins</term><term>Neural Pathways (radionuclide imaging)</term><term>Neurodegenerative Diseases (radionuclide imaging)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinsonian Disorders (radionuclide imaging)</term><term>Sensitivity and Specificity</term><term>Substantia Nigra (radionuclide imaging)</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term><term>Membrane Glycoproteins</term><term>Nerve Tissue Proteins</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Corpus Striatum</term><term>Neural Pathways</term><term>Neurodegenerative Diseases</term><term>Parkinson Disease</term><term>Parkinsonian Disorders</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Diagnosis, Differential</term><term>Humans</term><term>Sensitivity and Specificity</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We discuss the potential role of dopamine transporter (DAT) imaging by single photon emission computed tomography (SPECT) as a biological marker for differentiating among parkinsonian disorders in routine clinical practice, and the implication for disease progression assessment is considered. Although clinical criteria enable accurate and reliable diagnosis of fully developed Parkinson's disease, there are several areas of diagnostic uncertainty relating to atypical parkinsonian disorders, isolated tremor symptoms not fulfilling essential tremor criteria, as well as drug-induced and psychogenetic parkinsonism. DAT-SPECT facilitates differential diagnosis of the different parkinsonian syndromes that cannot be reliably separated on clinical grounds and it can thus provide valuable diagnostic information in early disease.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14531041</PMID><DateCreated><Year>2003</Year><Month>10</Month><Day>07</Day></DateCreated><DateCompleted><Year>2004</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>18 Suppl 7</Volume><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.</ArticleTitle><Pagination><MedlinePgn>S16-21</MedlinePgn></Pagination><Abstract><AbstractText>We discuss the potential role of dopamine transporter (DAT) imaging by single photon emission computed tomography (SPECT) as a biological marker for differentiating among parkinsonian disorders in routine clinical practice, and the implication for disease progression assessment is considered. Although clinical criteria enable accurate and reliable diagnosis of fully developed Parkinson's disease, there are several areas of diagnostic uncertainty relating to atypical parkinsonian disorders, isolated tremor symptoms not fulfilling essential tremor criteria, as well as drug-induced and psychogenetic parkinsonism. DAT-SPECT facilitates differential diagnosis of the different parkinsonian syndromes that cannot be reliably separated on clinical grounds and it can thus provide valuable diagnostic information in early disease.</AbstractText><CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poewe</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital, Innsbruck, Austria. werner.poewe@uibk.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scherfler</LastName><ForeName>Christoph</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493214">SLC6A3 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003342">Corpus Striatum</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050483">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D008562">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D026901">Membrane Transport Proteins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000032">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D009419">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009434">Neural Pathways</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019636">Neurodegenerative Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012680">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013378">Substantia Nigra</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D014055">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>45</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14531041</ArticleId><ArticleId IdType="doi">10.1002/mds.10573</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country><region><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><noCountry><name sortKey="Scherfler, Christoph" sort="Scherfler, Christoph" uniqKey="Scherfler C" first="Christoph" last="Scherfler">Christoph Scherfler</name></noCountry><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003649 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003649 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:14531041
|texte= Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:14531041" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |